Glycovax Pharma
Press releases
Université Laval and Glycovax Pharma Enter into an Exclusive Global Licens Agreement for the Development of Innovative Galectin-3 Inhibitors
Montréal and Québec City, 22 April 2026 — Université Laval and Glycovax Pharma announce an exclusive global license agreement granting Glycovax the rights to develop and commercialize a family of compounds targeting galectin-3, a cellular protein involved in multiple biological processes and recognized for its role in the development of numerous fibrotic diseases and other…
Glycovax Pharma, the National Research Council of Canada and the Université de Montréal, join forces to develop an innovative vaccine against the bacterium Pseudomonas aeruginosa (Pa), made possible through CQDM’s financial support
Fighting respiratory diseases, particularly in hospitals Montréal, Canada – October 8, 2025 – Glycovax Pharma today announced a strategic collaboration with the National Research Council of Canada (NRC) and the Faculty of Veterinary Medicine at the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa (Pa) infections. Funding for this project is made…
Glycovax Pharma is granted a licence by the National Research Council of Canada to develop a vaccine to fight nosocomial disease related to Pseudomonas aeruginosa (Pa)infections
Montreal, Canada, August 18, 2025 – Pseudomonas aeruginosa (Pa) is a bacterium responsible for nosocomial infections and is often fatal when contracted by people living with cystic fibrosis. There is currently no vaccine to prevent Pa-related infections even though this bacterium is a high-priority target for the World Health Organization (WHO). The National Research Council…
Glycovax Pharma launches a highly performant SLA Adjuvant
MONTREAL, Canada July 8, 2025 – Glycovax Pharma Inc. is taking an important step forward in its contribution to the vaccine industry with the large-scale production of sulfated lactosyl archaeol (SLA) archaeosomes, a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). This NRC license represents a major strategic development for…
Glycovax Pharma commercializes a more affordable CRM197 protein
Montreal, Canada, June 9, 2025 – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements…